JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.
Pharma & Biotech
Medical Devices & Diagnostics
Is Myriad setting a new performance and pricing benchmark in bioscaffold trauma use?
Can Aroa’s bioscaffold platform reshape trauma care economics? See what Myriad’s MASTRR data means for hospitals, surgeons, and reimbursement.
Medical Devices & Diagnostics
Medtronic expands Affera platform with Sphere-360 catheter CE Mark and IDE trial kickoff
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.
Pharma & Biotech
RED-C setback for Bausch Health: What this failed Phase 3 trial reveals about cirrhosis care gaps
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.
Medical Devices & Diagnostics
Nalu Medical’s wearable-powered PNS shows strong 24-month durability in COMFORT RCT
Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.
Medical Devices & Diagnostics
Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?
Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.
Pharma & Biotech
How ImmunityBio’s ANKTIVA combo is challenging glioblastoma’s immune collapse model
New Phase 2 data suggest ImmunityBio’s ANKTIVA plus CAR-NK combo could restore immune competence in glioblastoma. Find out why it matters.
Pharma & Biotech
Is deceased donor marrow a viable backup graft? First human data from Ossium says yes
Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.
Pharma & Biotech
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.
Pharma & Biotech
Brazil rollout puts Bavarian Nordic’s chikungunya vaccine under regulatory and execution scrutiny
Find out how Bavarian Nordic’s Brazil rollout with Eurofarma puts its chikungunya vaccine to the ultimate regulatory and execution test.